MedTrace Logo

Postoperative Analgesia After Minithoracotomy

NCT03415555 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-11-28

No results posted yet for this study

Summary

Patients scheduled for minimally invasive mitral valve replacement. Each patient will be treated with intravenous (i.v.) oxycodone - patient-controlled analgesia (PCA). Half of the patients will be randomly allocated to Erector Spinae Plane (ESP) blockade group.

Conditions

  • Postoperative Pain
  • Mitral Valve Disease

Interventions

PROCEDURE

Erector Spinae Plane blockade

Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.2 mL per patients' KG. The maximum dose is 40 mL.

DRUG

Oxycodone

Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.

PROCEDURE

general anesthesia

Each patient will generally anesthetized and endotracheal tube will be inserted

DRUG

paracetamol

Paracetamol will be given i.v. every 6 hours.

Sponsors & Collaborators

  • University of Rzeszow

    collaborator OTHER

  • Medical University of Lublin

    lead OTHER

Principal Investigators

  • Mirosław Czuczwar, M.D., PhD · Medical University of Lublin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-07
Primary Completion
2018-04-18
Completion
2018-04-18

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03415555 on ClinicalTrials.gov